AI Article Synopsis
- Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that enhance the immune system's ability to fight cancer by targeting specific proteins that downregulate immune responses.
- ICPIs have shown higher rates of durable responses in treating various cancers compared to traditional chemotherapy, but they can also lead to serious immune-related side effects, such as colitis and hepatitis.
- The review aims to address the diagnosis and management of these ICPIs-associated conditions and compare them with other diseases like inflammatory bowel disease and autoimmune liver disease.
Article Abstract
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates of durable responses in the metastatic setting far exceeding what would be expected from conventional chemotherapy. ICPIs have also been associated with rare but serious immune-related adverse events due to over-activation of the immune system that can affect any organ, including the gastrointestinal tract and liver. As the use of ICPIs in oncology continues to increase, ICPI-associated colitis and hepatitis will be encountered frequently by gastroenterologists and hepatologists. This review will focus on the diagnosis and management of ICPI-associated colitis and hepatitis. We will also compare these ICPI-related toxicities with sporadic inflammatory bowel disease and autoimmune liver disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143593 | PMC |
| http://dx.doi.org/10.1038/s41424-018-0049-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!